Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Orygen, Melbourne, Australia
  2. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  3. Corresponding author: Dr Maximus Berger, 35 Poplar Rd, Melbourne, VIC 3052, Australia ([email protected]).
  4. Orygen, Melbourne, Australia
  5. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  6. Orygen, Melbourne, Australia
  7. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  8. Department of Psychiatry, University of Melbourne, Melbourne, Australia
  9. Orygen, Melbourne, Australia
  10. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  11. Orygen, Melbourne, Australia
  12. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  13. Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia
  14. Orygen, Melbourne, Australia
  15. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  16. Orygen, Melbourne, Australia
  17. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  18. Institute for Health and Sport, Victoria University, Melbourne, Australia
  19. Burnet Institute, Melbourne, Australia
  20. Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, Australia
  21. School of Psychology, University of Sydney, Sydney, Australia
  22. Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, Australia
  23. School of Psychology, University of Sydney, Sydney, Australia
  24. Orygen, Melbourne, Australia
  25. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  26. Orygen, Melbourne, Australia
  27. Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia
  1. Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am. 2009;32(3):483–524. PubMed CrossRef
  2. Ginsburg GS, Becker EM, Keeton CP, et al. Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry. 2014;71(3):310–318. PubMed CrossRef
  3. Kessler RC, Ruscio AM, Shear K, et al. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010;2:21–35. PubMed CrossRef
  4. Copeland WE, Angold A, Shanahan L, et al. Longitudinal patterns of anxiety from childhood to adulthood: the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2014;53(1):21–33. PubMed CrossRef
  5. Cuijpers P, Cristea IA, Karyotaki E, et al. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry. 2016;15(3):245–258. PubMed CrossRef
  6. James AC, James G, Cowdrey FA, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2015;(2):CD004690. PubMed
  7. Strawn JR, Welge JA, Wehry AM, et al. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–157. PubMed CrossRef
  8. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342(mar11 1):d1199. PubMed CrossRef
  9. Dobson ET, Bloch MH, Strawn JR. Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry. 2019;80(1):17r12064. PubMed CrossRef
  10. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–774. PubMed CrossRef
  11. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836. PubMed CrossRef
  12. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799–1806. PubMed CrossRef
  13. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225–231. PubMed CrossRef
  14. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94. PubMed CrossRef
  15. Devinsky O, Cross JH, Laux L, et al; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–2020. PubMed CrossRef
  16. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278. PubMed CrossRef
  17. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. PubMed CrossRef
  18. Klier CM, de Gier C, Felnhofer A, et al. A case report of cannabidiol treatment of a Crohn’s disease patient with anxiety disorder. J Clin Psychopharmacol. 2020;40(1):90–92. PubMed CrossRef
  19. Shannon S, Lewis N, Lee H, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Permanente J.; 2019:23.
  20. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20(4):16–005. PubMed CrossRef
  21. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121–130. PubMed CrossRef
  22. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. PubMed CrossRef
  23. Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466. PubMed CrossRef
  24. McGorry PD, Goldstone SD, Parker AG, et al. Cultures for mental health care of young people: an Australian blueprint for reform. Lancet Psychiatry. 2014;1(7):559–568. PubMed CrossRef
  25. Headspace Australia. Annual Report 2019–2020; 2020.
  26. Anderson LL, Doohan PT, Oldfield L, et al. Citalopram and cannabidiol: in vitro and in vivo evidence of pharmacokinetic interactions relevant to the treatment of anxiety disorders in young people. J Clin Psychopharmacol. 2021;41(5):525–533. PubMed CrossRef
  27. Kevin RC, Vogel R, Doohan P, et al. A validated method for the simultaneous quantification of CBD, THC, and their metabolites in human plasma, and application to plasma samples from an oral CBD open label trial. Drug Test Anal. 2021;13(3):614–627. PubMed CrossRef
  28. Norman SB, Campbell-Sills L, Hitchcock CA, et al. Psychometrics of a brief measure of anxiety to detect severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Psychiatr Res. 2011;45(2):262–268. PubMed CrossRef
  29. Norman SB, Cissell SH, Means-Christensen AJ, et al. Development and validation of an Overall Anxiety Severity and Impairment Scale (OASIS). Depress Anxiety. 2006;23(4):245–249. PubMed CrossRef
  30. Moore SA, Welch SS, Michonski J, et al. Psychometric evaluation of the Overall Anxiety Severity And Impairment Scale (OASIS) in individuals seeking outpatient specialty treatment for anxiety-related disorders. J Affect Disord. 2015;175:463–470. PubMed CrossRef
  31. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: 2013.
  32. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
  33. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. PubMed CrossRef
  34. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  35. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329. PubMed CrossRef
  36. Allsop DJ, Norberg MM, Copeland J, et al. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119(1–2):123–129. PubMed CrossRef
  37. Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1):bjgpopen20X101010. PubMed CrossRef
  38. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043. PubMed CrossRef
  39. Amminger GP, Berger M, Rice SM, et al. Novel biotherapies are needed in youth mental health. Australas Psychiatry. 2017;25(2):117–120. PubMed CrossRef
  40. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139–154. PubMed CrossRef
  41. Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer Cannabidiol (CBD) use. J Clin Med. 2019;8(7):989. PubMed CrossRef
  42. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72(9):835–847. PubMed CrossRef
  43. Huezo-Diaz P, Perroud N, Spencer EP, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2012;26(3):398–407. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe